Structure (09b48fda 460a 496b 8644 Db205465d06c 01)
Donepezil Hydrochloride
Product Images NDC 42254-305
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 42254-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (09b48fda 460a 496b 8644 Db205465d06c 02)
The text describes the results of a clinical trial investigating the effects of different dosages of Donepezil Hydrochloride on patients with Alzheimer's disease. The figure shows the change in patients' ADAS-cog score (a measure of cognitive function) over a 24-week period. Patients receiving 10mg/day of Donepezil showed clinical improvement while patients receiving 5mg/day or placebo showed a decline or no change from baseline.*
Figure 2 (09b48fda 460a 496b 8644 Db205465d06c 03)
This appears to be a chart or graph showing the effectiveness of the drug Donepezil Hydrochloride in treating patients with ADAS-cog. The chart displays the cumulative percentage of patients and their respective change in ADAS-cog score. The treatment groups include a 10 mg/day dose, a 5 mg/day dose, and a placebo. It is difficult to provide further information without additional context.*
Figure 3 (09b48fda 460a 496b 8644 Db205465d06c 04)
The text describes a figure, showing the frequency distribution of CIBIC plus scores at week 24 for patients who have taken either Donepezil Hydrochioride 10 mg/day or Donepezil Hydrochioride 5 mg/day. The figure displays the percentage of patients who have had different levels of improvement or worsening of CIBIC-plus rating, ranging from markedly improved to markedly worse.*
Figure 4 (09b48fda 460a 496b 8644 Db205465d06c 05)
This is a figure depicting the time-course of clinical improvement of patients with Decline using two different doses of Donepezil Hydrochloride (10mg/day and 5mg/day) and Placebo for a 15-week study. The ADAS-cog Score was used to measure the change from baseline. No further information is available from this text.*
Figure 5 (09b48fda 460a 496b 8644 Db205465d06c 06)
This is a table displaying the changes in ADAS-cog scores of patients who were administered with different doses of Donepezil Hydrochloride (0 mg/day, 5 mg/day, 10 mg/day) and placebo in a clinical study. The figure shows the cumulative percentage of patients plotted against the change from baseline ADAS-cog scores. The study had a completion rate of 93% for Placebo, 90% for 5mg/day and 82% for 10mg/day treatment group.*
Figure 6 (09b48fda 460a 496b 8644 Db205465d06c 07)
This text appears to be a report of a study or clinical trial. It mentions the use of Donepezil Hydrochloride at different doses (10mg/day and 5mg/day) and the evaluation of its effects using a rating scale called CIBIC-plus. The text includes a graph showing the frequency distribution of scores on this scale at week 12. It also notes that there were some improvements observed but also some cases where there was worse or no change. Overall, this report suggests that Donepezil Hydrochloride may have some beneficial effects but also some limitations or potential side effects.*
Figure 7 (09b48fda 460a 496b 8644 Db205465d06c 08)
The text describes a figure plot showing the time course of the change from baseline in SIB score for patients who completed 6 months of drug treatment with either Donepezil Hydrochloride 10 mg/day or Placebo. The plot shows the mean change from baseline in SIB score over 3 and 6 months of drug treatment.*
Figure 8 (09b48fda 460a 496b 8644 Db205465d06c 09)
The text describes a figure labeled as "Figure 8" that shows the percentage of patients completing 6 months of double-blind treatment with changes from baseline in SIB (Severe Impairment Battery) scores. The graph compares the effects of Donepezil Hydrochloride (10 mg/day) versus Placebo. However, there is no sufficient context to draw any meaningful conclusion.*
Figure 9 (09b48fda 460a 496b 8644 Db205465d06c 10)
Figure 10 (09b48fda 460a 496b 8644 Db205465d06c 11)
This is a graph labeled "Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores." The graph shows the percentage of patients with Alzheimer's disease who completed six months of treatment with Donepezil Hydrochloride 10 mg/day and the corresponding changes from baseline in their ADCS-ADL-Severe Scores. There is additional text with various numbers and symbols that are not informative.*
Donepezil HCl 10mg (09b48fda 460a 496b 8644 Db205465d06c 12)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
